Trials / Active Not Recruiting
Active Not RecruitingNCT06646055
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
A Phase Ib/II Clinical Study of AK112 and Cadonilimab Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112, Cadonilimab, nab-paclitaxel, gemcitabine | IV infusion, specified dose on specified days. |
| DRUG | AK112, Cadonilimab, nab-paclitaxel, gemcitabine | IV infusion, specified dose on specified days. |
| DRUG | AK112, Cadonilimab, nab-paclitaxel, gemcitabine | IV infusion, specified dose on specified days. |
| DRUG | AK112, nab-paclitaxel, gemcitabine | IV infusion, specified dose on specified days. |
| DRUG | nab-paclitaxel, gemcitabine | IV infusion, specified dose on specified days. |
Timeline
- Start date
- 2025-01-21
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
- First posted
- 2024-10-17
- Last updated
- 2026-03-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06646055. Inclusion in this directory is not an endorsement.